Age: 6.0
Sex: F
Vaccine: COVID19, DTAPIPV, HEPA, PNC15, VARCEL
Symptoms: Accidental overdose, Vaccination site pain
Clinical narrative: The vaccination provider felt that the entire contents should be given to a patient as it is a single dose vial/Was given 0.5 ml when it should have been 0.25 ml; after vaccine no noticeable side effects besides achy shot site; This spontaneous case was reported by a medical assistant and describes the occurrence of VACCINATION SITE PAIN (after vaccine no noticeable side effects besides achy shot site) and ACCIDENTAL OVERDOSE (The vaccination provider felt that the entire contents should be given to a patient as it is a single dose vial/Was given 0.5 ml when it should have been 0.25 ml) in a 6-year-old female patient who received mRNA-1273.815 (MODERNA COVID-19 VACCINE 2023-2024) (batch no. AU5558B) for COVID-19 prophylaxis.    Co-suspect products included non-company products VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) (VARIVAX [VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK)]) for an unknown indication, HEPATITIS A VACCINE INACT (VAQTA) for an unknown indication, PNEUMOCOCCAL VACCINE CONJ 15V (CRM197) (VAXNEUVANCE) for an unknown indication and QUADRACEL for an unknown indication.    No Medical History information was reported.   On 26-Oct-2023, the patient received first dose of mRNA-1273.815 (MODERNA COVID-19 VACCINE 2023-2024) (Intramuscular use) .5 milliliter, first dose of VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK) (VARIVAX [VARICELLA ZOSTER VACCINE LIVE (OKA/MERCK)]) (Subcutaneous use) 1 dosage form, first dose of HEPATITIS A VACCINE INACT (VAQTA) (Intramuscular use) 1 dosage form, first dose of PNEUMOCOCCAL VACCINE CONJ 15V (CRM197) (VAXNEUVANCE) (Intramuscular use) 1 dosage form and first dose of QUADRACEL (Intramuscular use) 1 dosage form. In 2023, the patient experienced VACCINATION SITE PAIN (after vaccine no noticeable side effects besides achy shot site). On 26-Oct-2023, the patient experienced ACCIDENTAL OVERDOSE (The vaccination provider felt that the entire contents should be given to a patient as it is a single dose vial/Was given 0.5 ml when it should have been 0.25 ml). At the time of the report, VACCINATION SITE PAIN (after vaccine no noticeable side effects besides achy shot site) and ACCIDENTAL OVERDOSE (The vaccination provider felt that the entire contents should be given to a patient as it is a single dose vial/Was given 0.5 ml when it should have been 0.25 ml) outcome was unknown.        For mRNA-1273.815 (MODERNA COVID-19 VACCINE 2023-2024) (Intramuscular use), the reporter considered ACCIDENTAL OVERDOSE (The vaccination provider felt that the entire contents should be given to a patient as it is a single dose vial/Was given 0.5 ml when it should have been 0.25 ml) to be not related. No further causality assessment was provided for VACCINATION SITE PAIN (after vaccine no noticeable side effects besides achy shot site).    No Concomitant medications provided by the reporter. Patient had no allergies to medications, food, and other products. Patient had no acute illnesses at the time of vaccination and up to one month before and had no chronic or long-standing health conditions. No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-747540 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-747540: